EUVIMEDOpdag EUVIMED
Multizentrische StudieBeobachtungsstudie

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure

Paul J Clark, Patricia C Valery iD, Simone I Strasser, Martin Weltman, Alex Thompson, Miriam T Levy iD, Barbara Leggett, Amany Zekry, Y Julian Rong, Marie Sinclair iD, Jacob George iD, William Sievert and 5 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70219 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Paul J Clark and 16 co-authors. Institution: Department of Gastroenterology, Princess Alexandra and Mater Hospitals, and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, …. Major MEDLINE topics: Hepatitis C, Antiviral Agents, Mortality. Cited 3 times so far (Crossref); 40 references. Funded by: Commonwealth Department of Health, Merck, AbbVie.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Cure of hepatitis C virus (HCV) infection decreases liver‐ and all‐cause mortality. However, the risk of early mortality after HCV cure remains. We examined factors associated with cause‐specific mortality after direct‐acting antiviral (DAA) therapy.

Methods

DAA‐treated adults (recruited 2016–2021) were followed up to September 2023. Medication, health‐service use, and deaths were obtained from population databases. The primary outcome was all‐cause and cause‐specific mortality.

Results

Among 3619 patients (average 52.0 years (SD = 10.5), 66.0% male, 33.6% with cirrhosis) followed for a median of 6.8 years (IQR 5.5–7.4), 423 (11.7%) died (40.6% due to liver disease, 13.2% self‐harm/accidental poisoning and 12.3% respiratory disease/lung cancer). Cirrhosis (adjusted hazard ratio (adj‐HR) = 14.51, 95% CI 6.87–30.64), FIB4 > 3.25 (adj‐HR = 4.22, 95% CI 2.63–6.80), nonsustained virological response (SVR) (adj‐HR = 3.94, 95% CI 2.64–5.88) and age ≥ 60 years (adj‐HR = 1.88, 95% CI 1.32–2.69) increased liver‐related mortality risk. Mortality was threefold higher in non‐SVR (32.4% of 210 patients vs. 10.2% of 2894 with SVR, p < 0.001). Non‐SVR increased risk of liver mortality (adj‐HR = 4.30, 95% CI 2.90–6.37). Mental health medication use (adj‐HR = 2.82, 95% CI 1.40–5.67), loss to clinical follow‐up (adj‐HR = 2.61, 95% CI 1.31–5.21) and injection drug use/opioid replacement therapy (adj‐HR = 2.26, 95% CI 1.23–4.14) increased risk of self‐harm/accidental poisoning ‐related mortality . Age ≥ 60 years and diabetes increased mortality risk from other extrahepatic cancer (adj‐HR = 2.68, 95% CI 1.31–5.51 and adj‐HR = 2.57, 95% CI 1.15–5.72) and cardiovascular disease (adj‐HR = 2.71, 95% CI 1.06–4.19 and adj‐HR = 2.28, 95% CI 1.03–5.05).

Conclusions

Liver‐related death drives mortality for cirrhotic patients. Curing HCV remains critical. Holistic HCV care, with attention to mental health illnesses in younger patients, metabolic comorbidities, and better cancer screening for older patients may reduce excess mortality.

Subjects

MeSH terms (MEDLINE)

Hepatitis CAntiviral AgentsMortalityHumansMaleFemaleAdultMiddle AgedLiver DiseasesLung NeoplasmsPoisoningSuicide, CompletedRisk FactorsCardiovascular DiseasesProspective StudiesRegistriesAustraliaSurvival Analysis

Author keywords

cirrhosisdirect‐acting antiviralhepatocellular carcinomaliver diseaseliver fibrosis

Substances

Antiviral Agents

Authors and institutions

  • Department of Gastroenterology, Princess Alexandra and Mater Hospitals, and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • QIMR Berghofer Medical Research Institute, and Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.
  • Hepatology Services, Nepean Hospital, Penrith, New South Wales, Australia.
  • Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Gastroenterology and Liver, Liverpool Hospital, Sydney, New South Wales, Australia.

ORCID profiles: Patricia C Valery, Miriam T Levy, Marie Sinclair, Jacob George, Stuart K Roberts

Funding

  • Commonwealth Department of Health
  • Merck
  • AbbVie
  • Australian Government
  • Gilead Sciences

Cite

APA

Clark, P. J., Valery, P. C., Strasser, S. I., Weltman, M., Thompson, A., Levy, M. T., Leggett, B., Zekry, A., Rong, Y. J., Sinclair, M., George, J., Sievert, W., MacQuillan, G., Tse, E., Wade, A., Cheng, W., & Roberts, S. K. (2025). Surviving Hepatitis C—Understanding Death and Survival Beyond Cure. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70219

Vancouver

Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson A, Levy MT, et al. Surviving Hepatitis C—Understanding Death and Survival Beyond Cure. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70219

BibTeX
@article{Clark2025,
  author = {Clark, Paul J and Valery, Patricia C and Strasser, Simone I and Weltman, Martin and Thompson, Alex and Levy, Miriam T and Leggett, Barbara and Zekry, Amany and Rong, Y Julian and Sinclair, Marie and George, Jacob and Sievert, William and MacQuillan, Gerry and Tse, Edmund and Wade, Amanda and Cheng, Wendy and Roberts, Stuart K},
  title = {Surviving Hepatitis C—Understanding Death and Survival Beyond Cure},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70219}
}
Start for free →